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Abstract  
 
Applying CRISPR/Cas9-mediated mutagenesis to primary mouse 
immune cells, we used high-fidelity sgRNAs designed with a novel 
sgRNA design tool (CrispRGold) to target genes in primary B cells, T 
cells and macrophages isolated from a new Cas9 transgenic mouse line. 
Using this system, we achieved an average knockout efficiency of 80% 
in B cells. On this basis, we established a robust small-scale CRISPR-
mediated screen in these cells and identified new genes essential for B 
cell activation and plasma cell differentiation. This screening system 
does not require deep sequencing and may serve as a precedent for the 
application of CRISPR/Cas9 to primary mouse cells. 
 
Significance  
Efficient CRISPR/Cas9-mediated mutagenesis is necessary for robust 
genetic screening in primary cells and requires sufficiently high levels 
of Cas9 and reliable sgRNAs. We provide a new sgRNA design tool that 
selects high-fidelity sgRNAs and a new Cas9 transgenic mouse line that 
expresses Cas9 at high levels in all cells analyzed. Using  this system, 
we achieved an average knockout efficiency of 80% in primary B cells 
and established a robust CRSPR/Cas9-mediated genetic screening 
system that can be adapted to other primary cell types.  
  
 
  
The CRISPR/Cas9 technology is a powerful tool for gene editing (1-3). 
Application of this technology to primary cells is still in its initial phase, but 
promises to accelerate research. In many instances, such as the primary 
hematopoietic cells studied here, high knockout efficiencies are essential for 
studying gene function, as the limited life span of the cells often does not 
allow for selection and expansion of knockout clones prior to in vitro 
experiments. Moreover, screens that are based on readouts that do not affect 
survival require high knockout efficiencies to identify true positive hits. The 
two most decisive factors for high CRISPR/Cas9 knockout efficiencies are 
sufficient nuclear Cas9 levels and the selection of potent sgRNAs (4, 5). To 
overcome the requirement of Cas9 delivery to primary cells, transgenic mice 
expressing Cas9 and GFP from the Rosa26 locus have been generated (6; a 
related approach, targeting the hematopoietic system, has been lentiviral 
Cas9 transduction into hematopoietic stem cells, ref. 7). While primary 
dendritic cells of these mice have been successfully used for functional 
screening in vitro (6, 8), their lymphocytes express only low levels of GFP, 
and their use in CRISPR-mediated screens has not been reported so far. In 
addition, these mice were not generated on a pure C57BL/6 background. We 
thus generated a new C57BL/6 Cas9-transgenic line with an improved Cas9 
expression cassette (9). As we were interested in small-scale screening, a 
key consideration was to use only few, but reliable sgRNAs without the 
necessity of sgRNA-testing experiments prior to screening. Previous studies 
have shown large variations in sgRNA efficiencies (8, 10-12). Multiple sgRNA 
design programs have been developed, but none of them combines all the 
criteria that we developed in-lab to reach optimal sgRNA activity and 
specificity, including on-target efficiency, genome-wide off-target predictions 
taking into account the impact of mismatch-type and -position, targeting of all 
isoforms of genes, and conservation of functional secondary structure of the 
sgRNA (13). We thus developed a new sgRNA design tool that selects 
sgRNAs having high specificity, high on-target efficiency and intact secondary 
structure important for the recognition by Cas9. Combining this new program 
with our Cas9 transgenic C57BL/6 mice, we established an easy and robust 
screening method to study gene function in primary hematopoietic (and likely 
other) cells with high signal-to-noise ratio.  
  
Results 
 
Design of specific and efficient sgRNAs  
Coding genes typically contain hundreds of protospacer adjacent motif (PAM) 
sequences, allowing for a wide choice among possible sgRNAs. To design 
the most specific and efficient sgRNAs to target a gene or set of genes, we 
implemented our sgRNA design rules in a new tool that we termed 
CrispRGold. CrispRGold first projects the coding sequences (CDS) of the 
different isoforms of a gene to a single ‘minimal CDS’, in order to identify 
sgRNAs that would target most or all isoforms of that gene. For each sgRNA 
candidate, the position in the minimal CDS is stored and the sgRNA is aligned 
to the genome using the Burrows-Wheeler Aligner (BWA) (14) to identify off-
target sites. Based on the quantitative measurement of off-target site activity 
(15), we defined a type- and position-dependent mismatch-penalty matrix, 
such that the sum of mismatch-penalties (or mutation distance) for the various 
off-target sites would inversely correlate with the frequency of detected off-
target site activities (Fig. 1A and B). This mismatch penalty matrix especially 
weighs the increased impact of mismatches close to the 3’-end of the sgRNA 
and the decreased relevance of mutations causing wobble base pairing. 
CrispRGold uses this matrix to calculate the risk of each individual predicted 
off-target site genome-wide for a given sgRNA, sorts these sites according to 
their risk, and attributes a global off-target risk (or specificity score) to each 
sgRNA based on the three off-target sites with the highest risk. In addition, 
CrispRGold computes sgRNA-intrinsic properties, such as the GC-content 
and the folding energy between the targeting sequence and the scaffold-RNA 
of the sgRNA (16). A high binding energy between the targeting sequence 
and the scaffold may alter the secondary structure of the sgRNA and 
potentially disturb recognition of the sgRNA by Cas9 or binding of the 
targeting sequence to the DNA (Fig. 1C). Finally, CrispRGold goes through 
iterative loops of decreasing stringency to find the required number of 
sgRNAs per gene or sequence. In each loop, sgRNAs are prioritized 
according to their specificity (Fig. 1D).  
  
 
Characterization of a new Cas9 transgenic mouse line 
In the mice created by Platt et al. (6) (hereafter called R26-Cas9p2aGFP), the 
Cas9 protein is fused to eGFP via a self-cleaving P2A peptide. In our Rosa26-
LSL-Cas9iGFP mice, generated by CRISPR-mediated editing of C57BL/6 
zygotes, Cas9 is also expressed from the Rosa26 locus in a Cre-dependent 
manner, but with the Cas9 coding sequence linked to eGFP via an internal 
ribosomal entry site (IRES) (9). To apply the CRISPR/Cas9 technology to 
primary immune cells, we generated Cas9-transgenic mice with ubiquitous 
expression of Cas9 by crossing Rosa26-LSL-Cas9iGFP with Cre-deleter mice 
(Fig. 1E). We then evaluated the expression of Cas9 in the resulting R26-
Cas9iGFP/+ animals by monitoring GFP reporter levels by FACS. All 
hematopoietic sub-populations analyzed exhibited high GFP levels, including 
hematopoietic stem cells (HSC) in the bone marrow (BM), and various 
hematopoietic lineages, such as T, B and myeloid cells, independent of their 
anatomical location (Fig. 1F,G and Fig. S1A,B and C). The percentages of 
HSCs, B cells, T cells and myeloid cells were similar between R26-
Cas9iGFP/+ and control mice, indicating that the expression of Cas9iGFP is 
not toxic to any of these cell types (Fig. 1H). GFP levels in R26-Cas9iGFP/+ 
mice were higher than in R26-Cas9p2aGFP/+ mice (6), likely due to the 
presence of the IRES instead of the P2A peptide between Cas9 and GFP 
(Fig. S2A and B). To confirm that Cas9 is indeed present in the GFP+ cells, 
we performed western blotting on splenic B cells that were activated in vitro 
and on BM-derived macrophages (BMDM). In both cases, we detected high 
levels of Cas9 protein (Fig. S3A). Moreover, Cas9 was localized in the 
nucleus in the BMDM (Fig. S3B). Thus, primary immune cells of R26-
Cas9iGFP/+ animals express high levels of GFP and nuclear Cas9 to non-
toxic levels, allowing for genome editing and easy discrimination of Cas9+ and 
Cas9- cells in subsequent experiments.  
 
 
 
Efficient CRISPR/Cas9-mediated mutagenesis in primary immune cells  
To assess the knockout efficiency of the sgRNAs designed by CrispRGold in 
primary immune cells, we first selected 12 genes encoding B cell surface 
markers and designed 2 sgRNAs per gene (Fig. S4A). These sgRNAs were 
individually cloned into retroviruses bearing a BFP reporter and a Puromycin 
resistance gene. We then isolated B cells from wildtype and R26-Cas9iGFP/+ 
mice and mixed them in a 1:4 ratio, such that we could use the Cas9- (GFP-) 
cells as internal controls. These mixed B cells were activated with anti-CD40 
antibodies and IL-4 for 2 days and then transduced with retroviral particles. 
The transduced cells were further cultured on 40LB feeder cells (17) (NIH3/T3 
cells stably expressing CD40 ligand and BAFF) in the presence of IL-21 and 
Puromycin (Fig. 2A). Four days after transduction, all sgRNAs had led to cell 
surface marker knockouts, mostly with very high efficiency and an average 
knockout frequency above 70% (Fig. 2B,C and Fig. S4B). Only one sgRNA 
led to significantly lower knockout efficiencies due to a previously unknown 
sequence peculiarity (R.G., unpublished data), now implemented in 
CrispRGold. To confirm that these high knockout efficiencies are not unique to 
B cells, we performed a similar experiment using primary T cells that we 
activated with anti-CD3 and anti-CD28 (Fig. S5A). Four days after 
transduction with retroviral particles encoding sgRNAs against CD44, about 
50% of the cells showed a complete knockout of CD44 (Fig. 2D). Finally, to 
determine if we reach similarly high knockout frequencies in quiescent primary 
myeloid cells, we differentiated bone marrow cells into resting BMDMs using 
M-CSF and transduced them with lentiviral vectors expressing sgRNAs 
targeting CD64 and CD14 (Fig. S5B). Four days after transduction, 40-80% of 
the cells showed a knockout of the targeted genes (Fig. 2E and Fig. S5C). 
Thus, primary immune cells of R26-Cas9iGFP/+ mice are suitable for 
CRISPR/Cas9-mediated genome editing, and CrispRGold designs reliably 
highly efficient sgRNAs. In addition to the intrinsic properties of sgRNAs, the 
on-target dosage of sgRNA/Cas9 complexes is essential for efficient 
mutagenesis. The lower GFP levels in lymphocytes of R26-Cas9p2aGFP/+ 
mice (6) suggested that they have lower levels of Cas9 than the R26-
Cas9iGFP/+ mice here described. To compare the impact of Cas9-dosage on 
knockout efficiency, we thus repeated the experiment depicted in Fig. 2A, 
using the same sgRNAs and B cells of both Cas9-transgenic lines side by 
side. Indeed, all sgRNAs tested led to significantly lower knockout efficiencies 
in B cells from R26-Cas9p2aGFP/+ mice compared to R26-Cas9iGFP/+ mice 
(Fig. 2F,G and Fig. S3C), consistent with lower Cas9 levels in these cells (Fig. 
S3D). Thus, the combination of optimal sgRNAs and high levels of Cas9 in 
primary cells of R26-Cas9iGFP/+ mice led to the high knockout efficiencies 
observed in primary cells isolated from these animals.  
 
Robust inactivation of transcription factors known to be important for B 
cell differentiation 
Extending the analysis to transcription factors (TFs), we selected 5 TFs, 
Prdm1, Irf4, Myc, Xbp1, and Pou2af1, that are known to be important for B 
cell survival, proliferation and differentiation (18-24) (Fig. S6A). We designed 
3 sgRNAs per TF (Fig. S6B) and performed retroviral transduction 
experiments as before, but this time analyzing B cell survival and plasma cell 
differentiation (Fig. 3A). Expression of sgRNAs targeting Xbp1, Irf4, Pou2af1 
and Myc led to a strong survival disadvantage of Cas9-expressing cells, 
indicated by the decreased percentage of GFP+ cells (Fig. 3B,C and Fig. 
S6C). As for plasma cell differentiation, monitored by CD138 expression, 
targeting of all 5 TFs led to a strong block of differentiation (Fig. 3D,E and Fig. 
S6D). These findings are consistent with previous reports, showing that Xbp1, 
Irf4, Pou2af1 and Myc are important for both B cell survival, proliferation and 
terminal differentiation (18-22), whereas Prdm1 is only important for the latter 
(23, 24). Moreover, in all cases, the 3 individual sgRNAs showed a strong and 
consistent effect on the biological readout, further demonstrating that sgRNAs 
designed by CrispRGold work with high efficiency and consistency.  
 
Identification of novel genes important for B cell activation and plasma 
cell differentiation  
Benefitting from the robustness of our system and the consistently high 
knockout frequencies, we performed a small-scale screen to identify novel 
genes important for B cell proliferation and terminal differentiation. Based on a 
microarray analysis of B cells and plasma cells isolated from immunized mice, 
we selected 83 candidate genes up-regulated during plasma cell 
differentiation in vivo (Fig. S7). We designed one sgRNA against each of 
these genes and 13 control genes. We then performed the same experiment 
as before in a 96-well system, using the percentage of GFP+ and CD138+ 
cells as readout for survival/proliferation and plasma cell differentiation, 
respectively (Fig. 3A and Fig. S8A). Based on two experiments, which led to 
highly consistent results, we identified 22 genes to have a strong impact on 
survival/proliferation and 8 genes to selectively affect plasma cell 
differentiation (Fig. 3F,G and Fig. S8B). The 22 genes important for B cell 
survival/proliferation contained genes whose function in this context was 
previously unknown, such as Egr2, Dis3, Ost4, Preb and Pomp, which we 
validated in further experiments (Fig. S9A). Dis3 is potentially involved in 
immunoglobulin class switch recombination via targeting AID (25), whereas 
Pomp might be involved in plasma cell differentiation (26). Furthermore, we 
identified Arf4, Creld2 and Zfp36 among the novel genes enhancing or 
blocking plasma cell differentiation (Fig. 3H and Fig. S9B). Of note, mice 
deficient for Zfp36 have been shown earlier to develop autoimmune disease, 
a finding that could connect to our observation of enhanced plasma cell 
differentiation in its absence (27). These results show that the screening 
system as described here leads to clear and consistent functional results, 
permitting small-scale screens in primary mouse cells without the need of high 
numbers of sgRNAs per gene or deep sequencing.  
 
Discussion 
We provide a new and flexible sgRNA design tool that reliably identifies highly 
specific and efficient sgRNAs for a given set of genes or DNA sequences. 
CrispRGold can also be used for other organism, and will be available on a 
web platform. Primary cells of R26-Cas9iGFP/+ mice express high levels of 
GFP and Cas9 to non-toxic levels, allowing for efficient CRISPR-mediated 
gene editing and the use of GFP- internal controls. We show that these tools 
can be combined in an easy and robust screening assay of CRISPR 
mutagenesis in primary hematopoietic cells, and identify novel genes 
important for B cell activation and terminal differentiation. The same approach 
can be easily applied to other types of primary cells. 
 
Methods 
 
Mice 
Cas9 knock-in mice were reported previously (9).  Briefly, we knocked a 
Cas9-IRES-GFP cassette preceded by a LoxP-flanked Stop cassette into the 
mouse Rosa26 locus. The LSL-Cas9 mice were bred with Cre-deleter mice to 
generate Cas9 transgenic mice (available on Jackson Laboratory, stock No. 
028555). The C57BL/6 mice were obtained by local breeding. The 
heterozygous R26-Cas9p2aGFP/+ mice were purchased from the Jackson 
Laboratory (Stock No: 026179). BALB/c mice were from Charles River 
Laboratories. For the microarray of in vivo generated plasma cells, BALB/c 
mice were immunized intraperitoneally with 100!g phOx coupled to chicken 
serum albumin (CSA), precipitated with aluminum hydroxide. After 6–8 weeks, 
mice were boosted intravenously with 100!g soluble antigen. Plasma cells 
were sorted from spleen and the BM at day 6 and day 60 after secondary 
immunization. Animal experiments were approved by the Institution Animal 
Care and use Committee. 
 
CrispRGold 
Minimal CDS (minCDS) are generated based on the refseq tables (mm9). 
sgRNA candidates are defined by the presence of NGG and cutting site inside 
the minCDS. sgRNA candidates are mapped to the mouse genome (mm9) 
using BWA (14) (version 0.7.12) to identify potential off-target sites, ignoring 
the first base of the targeting sequence and allowing for 4 mismatches. The 
folding energy between the targeting sequence and the scaffold RNA is 
calculated using RNAduplex (Vienna Package) (16). CrispRGold is written in 
Perl, as all scripts that were implemented in CrispRGold if not otherwise 
stated. Briefly, sgRNA candidates are processed and scored as described in 
the main text. The first loop considers sgRNAs within the first 45% of the 
minCDS, with Tm <= 60°C, the lowest off-target risk score > 11, a scaffold-
folding energy <= 20 kcal/mol, targeting the max N isoforms, without low-
efficiency features and distance to the CDS-start >= 50 nts. The second loop 
considers sgRNAs as the first loop, but within the first 60% and with the 
lowest off-target risk score > 6. The third loop considers sgRNAs as the 
second loop, but with Tm <= 65°C and distance to CDS-start >= 10 nts. The 
fourth loop considers sgRNAs as the third loop, but with distance to the CDS-
start >= 1nt and neglecting Tm, scaffold-folding energy and low-efficiency 
features. The last loop considers sgRNAs as the fourth loop, but extending 
the search space to 90% oft the minCDS.  
 
96-well cloning approach 
The MSCV_hU6_CcdB_PGK_Puro_T2A_BFP vector was generated by 
cloning the PCR-amplified hU6-BbsI-CcdB-BbsI-gRNA fragment into the SalI 
and XhoI sites of the MSCV vector. The PGK-Puromycin-T2A-BFP fragment 
was amplified by overlapping PCR and cloned into the MluI site of the MSCV- 
hU6-BbsI-CcdB-BbsI-gRNA vector. For generating the mini-library, forward 
and reverse oligos were separately ordered in 96 deep-well plates. Each 
forward and reverse oligo was mixed and phosphorylated individually. Then 
annealed oligo duplexes were cloned into the BbsI sites of the  
MSCV_U6_CcdB_PGK_Puro_T2A_BFP vector. The plasmids were 
transformed into DH5! bacteria using a heat-shock 96-well system. After 30 
min pre-culture at 37°C, the transformed bacteria were transferred into 96 
deep-well plates containing 1.5ml LB liquid medium and sealed with PCR 
seals (Thermo Scientific). These plates were cultured for 12 h then split into 2 
new 96 deep-well plates and further cultured for 10-12h. Bacteria were 
collected by centrifugation at 4000 rpm for 1 min and plasmids were isolated 
using the NucleoSpin" 96 plasmid core kit (Macherey-Nagel).  
 
Cell culture 
Retroviral Plat-E packaging cells were maintained in DMEM (Gibco) supplied 
with 10% FCS (Gibco), 2mM L-Glutamine (Gibco), and 2mM Sodium Pyruvate 
(Gibco). 40LB feeder cells, producing BAFF and CD40L, were previously 
generated by Nojima et al(17) and maintained in completed DMEM medium. 
To prepare the feeder layer, 40LB feeder cells were irradiated with 12G# and 
plated at 5x104 cells/cm. Naïve B cells were isolated from the spleen of R26-
Cas9iGFP/+, R26-Cas9p2aGFP/+ or C57BL/6 mice by depletion of CD43+ 
cells using CD43 microbeads (Miltenyi Biotec). Resting B cells were plated at 
106 cells/ml in DMEM (Gibco) supplied with 10% FCS (Gibco), 2mM L-
Glutamine, 2mM Sodium Pyruvate, 2mM HEPES (Gibco), 1x NAA (Gibco), 
beta-mercaptoethanol (Sigma), and 10µg/ml Gentamicin (Lonza). Cas9 
(GFP+)-expressing B cells were mixed wildtype (GFP-) B cells and stimulated 
with anti-CD40 antibody (Biolegend) and IL-4 (Perprotech) for 48h before 
retroviral transduction. 
 
High-throughput retroviral production 
Plat-E cells were plated at 2.2x104 cells/100µl medium in each well of 96-well 
plates at day 0. 1 day later, the cells were transfected with 100ng DNA using 
Fugene"HD transfection reagents (Promega). 12 h after transfection, the 
supernatant was discarded and the cells were cultured with 150µl new 
complete medium. The transfected cells were cultured in a 32°C incubator for 
24 h. The retroviral supernatant was collected 48 h and 72 h after transfection 
into 96 deep-well plates. The 96-deep-well plates with supernatant were 
centrifuged at 1300 rpm for 5 min and the supernatant was transferred into 
new 96 deep-well plates and stored at -80°C. 
 
High-throughput retroviral transduction 
48 h after stimulation, GFP+/GFP- mixed B cells were harvested and re-
suspended at a density of 2x105 cells/ml in completed B cells medium 
supplied with 16µg/ml Polybrene (Sigma). 100µl cell suspension were 
transferred into each well of 96-well plates and 100µl of retroviral supernatant 
were added, then activated B cells were spin-transduced at 2500rpm for 
90min. The 96-well plates were placed in a 37°C incubator and on then next 
day the transduced GFP+/GFP- B cells were transferred into 96-well 40LB 
feeder cell plates in the presence of 20ng/ml of IL-21 (Perprotech) and were 
selected with 1.25µg/ml Puromycin (Sigma). The transduced GFP+/GFP- B 
cells were harvested and analysed at different time points by using BD 
Fortessa with a 96-well HTS unit.  
 
 
 
T cell activation and transduction 
Total T cells were isolated from R26-Cas9iGFP/+ and C57BL/6 mice using 
Pan T Cell Isolation Kit II, mouse (Miltenyi Biotec) and subsequently CD4 and 
CD8 T cells were sorted by FACS, the Cas9 (GFP+)-expressing T cells were 
mixed with wild-type (GFP-) T cells and activated with plate-bound anti-CD3 
(145-2C11, Biolegend) and anti-CD28 (37.51, Biolegend) in the presence of 
25 ng/ml rmIL-2 (Peprotech) for 2 days. The activated T cells were spin-
transduced with retroviral particles expressing sgRNAs. The transduced T 
cells were selected with Puromycin for 4 days. After Puromycin selection, the 
transduced T cells were analysed by flow cytometry or sorted. 
 
BMDM generation and lentiviral transduction 
BM-derived macrophages were differentiated from total mouse bone marrow 
cells for 14 days in macrophage growth medium (Dubelco’s modified medium 
(DMEM) with 10% FCS, 20% L-cell supernatant, 1% sodium pyruvate, 1% L-
Glutamine). sgRNAs targeting CD64 and CD14 surface makers were cloned 
into BbsI sites of pLKV-U6gRNA(BbsI)-PGKPuroP2ABFP vector (Addgene, 
#50946). Lentiviral particles were produced at the Centre International de 
Recherche en Infectiologie (CIRI) U1111/UMR5308 Inserm-CNRS-UCBL-
ENS de Lyon (Lyon, France). BMDMs were seeded at a density of 2x105 cells 
per well of 24 well plates and transduced with lentiviral supernatant for 4 
hours. The medium was then replaced and 2 days later transduced cells were 
selected with 2 µg/ml Puromycin for 4 days. The transduced BMDMs were 
analysed by FACS. 
 
FACS analysis and sorting 
For FACS analysis, single cell suspensions were prepared from the bone 
marrow, spleen, peritoneal cavity and mLN from R26-Cas9iGFP/+, R26-
Cas9p2aGFP/+ or C57BL/6 mice and cells were blocked with Fc#R antibody 
(Biolegend) for 10 min. The surface antigens were stained with fluorescent-
conjugated antibodies for 15 min. The cells were washed with FACS buffer 
(PBS/1%BSA) and analysed by BD Fortessa. The data was analysed by 
FlowJo software.  
For cell sorting, the BFP+ (sgRNA) GFP+ (Cas9) cells were sorted into 15ml 
Falcon tubes and centrifuged prior to DNA isolation for further analaysis. For 
single cell sequencing analysis, single BFP+GFP+ cells were sorted into 96-
well plates containing 5µl of DNA quick extraction buffer (Epicenter). The 
plates were briefly centrifuged and DNA was denatured and PCR was 
performed. 
 
Immunofluorescent staining and western blotting  
1x105 BMDMs were transferred into lysine-coated coverslip and further 
cultured for 24 hours. The cells were washed with cold PBS and fixed with 4% 
of Paraformaldehyde for 20 min at room temperature (RT). The cells were 
washed and permeabilized with PBS/0.25% TritonX-100 for 10 min at RT. The 
cells were washed and stained overnight with anti-Flag tag M2 antibody at 
4°C. Anti-Flag tag antibody was developed with rat anti-mouse IgG1 PE 
(Biolegend) for 1h at room temperature. The nuclei were counterstained with 
DAPI (Sigma). The images were analyzed by Keyence fluorescent 
microscopy. To detect Cas9 protein, activated B cell and BMDM lysates were 
run on SDS-PAGE gel and transferred into PVDF membrane (Healthcare). 
The Cas9 protein was developed with anti-Flag tag and anti-Cas9 antibodies; 
 $-actin was used for loading controls. 
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Figure legends 
 
Fig. 1. Design of efficient sgRNAs and characterization of new Cas9-
transgenic animals.  
(A) Heatmap showing mismatch penalties depending on the position within  
the targeting sequence of the sgRNA and the type of mismatch. Scores were 
chosen to fit the off-target frequencies detected by Tsai et al.   
(B) Dotplot of the predicted inverse offtarget risk of each off-target site of the 
VEGFA_3 sgRNA versus the reported GUIDEseq read numbers. Read 
numbers were extracted from Tsai et al. 
(C) Predicted secondary structure of two sgRNAs targeting mouse Btk. 
sgRNAs with low binding energy between the targeting sequence and the 
scaffold RNA do not disturb the secondary structure of the scaffold RNA (left), 
in contrast to sgRNAs with high binding energies between the targeting 
sequence and the scaffold RNA (right). 
(D) Scheme of the CrispRGold sgRNA design tool. 
(E) Scheme of the R26-LSL-Cas9iGFP allele before (top) and after crossing 
to Cre-deleter mice (bottom). Cre-mediated removal of the LSL cassette leads 
to ubiquitous expression of Cas9 and GFP in the entire mouse. 
(F) FACS analysis of GFP expression in hematopoietic stem cells (HSC), 
defined as the Lin-,CD45+,Sca1+cKit+ LSK population. LSK cells from wildtype 
C57BL/6 mice (red) and R26-Cas9iGFP/+ mice (blue) are shown on the same 
FACS plot (right). 
(G) FACS analysis of GFP expression in B cells (CD19+), monocytes/dendritic 
cells (CD11b+), granulocytes (Gr-1+) and T cells (CD3+). Cells were isolated 
from the BM (top) or spleen (bottom). Cells from wildtype C57BL/6 mice (red) 
and R26-Cas9iGFP/+ mice (blue) are shown in the same FACS plots.  
(H) Percentages of the indicated cell populations within all cells in the BM 
(left) or the spleen (right) of wildtype animals (red) or R26-Cas9iGFP/+ 
animals (blue). Each dot represents one mouse.  
 
 
 
 
Fig. 2. Efficient CRISPR-mediated gene inactivation in primary immune 
cells. 
(A) Scheme of CRISPR-mediated gene knockout in Cas9-expressing B cells. 
Splenic B cells isolated from wildtype and Cas9 transgenic mice were mixed 
at a 1:4 ratio. These cells were activated with anti-CD40 and IL-4 for 2 days 
and transduced with retroviral particles expressing specific sgRNAs and a 
Puromycin resistance gene. One day after transduction, the cells were 
transferred into 40LB feeder cell plates and cultured in the presence of IL-21 
and Puromycin.  
(B) FACS plots of CD19+BFP+ cells targeted with sgRNAs against B220 (left), 
CD24 (middle) and CD44 (right) 4 days after transduction. Knockout 
efficiencies were calculated based on the GFP+ cells that lost the surface 
marker (sub-gates of the GFP+ population).  
(C) Summary of the knockout efficiencies for the 12 indicated surface marker 
genes with 2 sgRNAs/gene. Knockout efficiencies were determined by FACS 
4 days after transduction of Cas9-expressing primary B cells with the 
respective sgRNAs. 
(D) FACS plots showing the CD44 knockout efficiency in Cas9-expressing 
primary T cells. Mixed Cas9 (GFP+) and wildtype (GFP-) splenic T cells were 
activated and transduced with retroviral particles expressing sgCD44-1 and 
sgCD44-2. The gates indicate the knockout efficiency in GFP+ T cells.  
(E) FACS plots showing the knockout efficiency of CD64 and CD14 in non-
dividing primary BMDMs. BMDMs from C57BL/6 (top) and R26-Cas9iGFP/+ 
(bottom) mice were transduced with lentiviruses expressing sgCD64-2 and 
sgCD14-2.  
(F) FACS plots of knockout efficiencies in primary B cells from R26-
Cas9iGFP/+ (upper panel) and R26-Cas9p2aGFP/+ (lower panel) mice, using 
the same setup as in (a) and sgRNAs against B220, CD24 and CD44. 
(G) Summary of knockout efficiencies using primary B cells from R26-
Cas9iGFP/+ (blue) and R26-Cas9p2aGFP/+ (red) mice. 
 
 
 
Fig. 3. Identification of novel genes involved in B cell activation and 
differentiation using robust CRISPR-mediated screening. 
(A) Scheme of CRISPR-mediated screening in primary B cells. GFP+ splenic 
B cells from R26-Cas9iGFP/+ mice were mixed with GFP- wildtype B cells 
and treated as indicated in the 96-well system. The cells were analysed by 
flow cytometry at the indicated time points. 
(B) FACS analysis of mixed GFP+/GFP- B cells 4 or 6 days after transduction 
with empty vector (control), sgPrdm1-1, sgXbp1-1, sgPou2af1-1, sgIrf4-1 or 
sgMyc-1. The gates show the percentage of GFP+ and GFP- B cells after 
gating on BFP+ cells. 
(C) Heatmap of the percentages of GFP+ B cells at day 4, 6 or 8 normalized to 
day 2. One control sgRNA and three different sgRNAs per TF were used to 
knockout Prdm1, Xbp1, Pou2af1, Irf4 or Myc.  
(D) FACS analysis of plasma cell differentiation, indicated by the expression 
of CD138, in the same experiment as in (b). Gates are set on CD138+ 
plasmablasts in GFP- (top) and GFP+ (bottom) cells.  
(E) Heatmap of the percentages of CD138+ plasmablasts within the GFP+ 
and GFP- at the indicated time points.  
(F) Fold changes of the percentages of GFP+ B cells at day 8 after 
transduction with sgRNAs against the candidate genes in two independent 
experiments. The repressor genes are indicated in green and the enhancer 
genes are shown in magenta. Fold changes were normalized to the initial 
percentage of GFP+ cells. 
(G) Fold changes of the percentages of CD138+GFP+ plasmablasts at day 8 
in the same experiment as in (F). The repressor genes are indicated in blue 
and the enhancer genes are shown in red. 
(H) Validation of the newly identified genes important in plasma cell 
differentiation. Histogram showing the percentages of GFP+CD138+ and GFP-
CD138+ plasmablasts 6 days after transduction with sgRNAs targeting 
Rosa26, Prdm1, Ost4, Arf4, Creld2, Zfp36 and Edem1.  
EG
isoform A
isoform B
isoform C
Minimal 
CDS
Speci!city
E!ciency
CDS Position
sgRNA struct.
sgRNA candidates
> genome wide o"-target
    site identi#cation 
> sgRNA properties
 0%  CDS position  100%
sgRNAs
Found?
Yes
No
Iterative Loops
Relaxing stringency
after each loop
BA
0 5 10 15
2
4
6
8
10
12
Inverse off-target risk
De
te
cte
d 
of
f-t
ar
ge
t h
its
 [lo
g2
(re
ad
s)
]
Mouse  Rosa26-­Cas9iGFP  locus
1 2pAEGFPIRES3xFlag-­Cas9STOP
LoxPLoxP
CAG
SA
5’
x  Cre-­deleter
1 25’
C
D
19
C
D
11
b
G
r-­
1
C
D
3
Cas9-­iGFP
B  cells
Monocytes
Dendritic  cells Granulocytes T  cells
Bone
marrow
Spleen
C57BL/6
R26-­Cas9iGFP/+
D
C
Functional  sgRNA  
structure
Disturbed  sgRNA
structure
LS
K  
Pr
o/P
re-­
B
Im
m/
Re
-­B
My
elo
id T B
My
elo
id T
0
5
10
10
20
30
40
50
60
70
80
%
  o
f  t
ot
al
  c
el
ls
C57BL/6 R26-­Cas9iGFP/+
BM Spleen
H
U G
G
U
G
C
U
G
C
UG
UUGG
CUC
CGGU
U
U U A
G A G C U A G
AAAUAGC
A
A
G
U
UAAAA
U
A
A
G
G
C
U A
G
UC
CG
U
U
A
U
C
A
A
C
U
U
GA
A
A
AA
G
U
G
G
C
A
C
C
G
A
G
U C
GGU
G
C
U
U
UUUU
GAAUCUUUCCCAUGAGA
AGCGUUUUAGA
GCUAG
A
A A
U A
G CAA
GU
U A
A A
A UAA
GG
CU A
G
UC C G U U A
U
C
A
A C U UG A
AAAAG
U
GG
CA
CC
G A
GU
CGGUGCUU
UUU
U
Targeting  sequence
Scaffold  RNA  stem
bound  by  Cas9
pAEGFPIRES3xFlag-­Cas9
LoxP
CAG
SA
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
TtoG
TtoC
TtoA
GtoT
GtoC
GtoA
CtoT
CtoG
CtoA
AtoT
AtoG
AtoC
1 2 3 4 5 6
Mismatch penalty
0
40
80
Co
un
t
Position in sgRNA
Target  site
Off-­target  sites
Li
n
CD45
Lin<CD45+BM  cells
18
C
ki
t
Sca1
Ckit+Sca1+  LSK
S
S
C
Cas9-­iGFP
C57BL/6
R26-­Cas9iGFP/+
2.23
F
18
Re
la
x
inverse
o!-target risk:
sum(penalties)
Primary  T  cells
sgCD44-­1 sgCD44-­2
D
CD64 CD14
FS
C
sgCD64-­2 sgCD14-­2
2.88 3.08
81.8 81.5
E
R26-­Cas9iGFP/+
C57BL/6
70-­80%
20-­30%
_-­CD40
+IL-­4
Retroviral  
transduction
IL-­21 IL-­21
+Puro40LB  feeder  
cells
FACS
A
B  cells
Primary  BMDMs
48
13
92
55
85
50
90
54
91
56
85
49
sgB220-­1 sgB220-­2 sgCD24-­1 sgCD24-­2 sgCD44-­1 sgCD44-­2
R
26
-­C
as
9i
G
FP
/+
R
26
-­C
as
9p
2a
G
FP
/+
GFP
B
22
0
C
D
24
C
D
44
Primary  B  cells
C
57
B
L/
6
R
26
-­C
as
9i
G
FP
/+
B
22
0
19.3 40.7
38.8
19.1 5.6
71.7
sgB220-­1 sgB220-­2 sgCD24-­1 sgCD24-­2 sgCD44-­1 sgCD44-­2
16.9 9.8
71.9
16.7 6.4
75.5
12.7 7.8
77.8
17.0 13.3
68.5C
D
24
C
D
44
Cas9-­iGFP
B Primary  B  cells
C
B2
20
CD
19
CD
24
CD
38
CD
44 Fa
s
CD
22
CD
80
CD
86
CD
83
CD
81
Tn
frs
f13
b
0
20
40
60
80
100
K
no
ck
ou
t  (
%
)
sgRNA-­1 sgRNA-­2
F G
31.7 30.4
30.27.73
30.6 43.0
22.93.54
C
D
44
Cas9-­iGFP
sg
B2
20
-­1
sg
B2
20
-­2
sg
CD
24
-­1
sg
CD
24
-­2
sg
CD
38
-­1
sg
CD
38
-­2
sg
Fa
s-­1
sg
Fa
s-­2
sg
CD
44
-­1
sg
CD
44
-­2
0
20
40
60
80
100
K
no
ck
ou
t  (
%
)
R26-­Cas9iGFP/+ R26-­Cas9p2aGFP/+
IL-­21 IL-­21  +  Puromycin  
Day  -­2 Day  0 Day  2 Day  4
FACS  analysis
Naive  B  cells
_-­CD40  +  IL-­4
Day  6 Day  8
Retroviral  transductionA C
Day  2  before  
Puromycin  selection
Cas9-­iGFP
FS
C
Control sgPrdm1-­1 sgXbp1-­1 sgPou2af1-­1 sgIrf4-­1 sgMyc-­1
Day  4
Day  8
Control sgPrdm1-­1 sgXbp1-­1 sgPou2af1-­1 sgIrf4-­1 sgMyc-­1
Cas9-­iGFP
FS
C
C
D
19
CD138
GFP<  cells
GFP
  cells
B
D
78.821.2 72.927.1 66.533.573.326.7 36.563.5 57.842.3 28.171.9
80.519.5 77.622.4 26.273.8 14.685.4 16.183.9 9.3390.7
17.6
16.8 19.2
1.33
24.8
9.82
18.9
8.10
28.9
9.05
17.4
4.53
80.519.5
FS
C
Cas9-­iGFP
0.2 0.6 1
Value
0
5
10
Co
un
t
Control
sgRNA-­1
sgRNA-­2
sgNRA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
Day  2 Day  4Day  6Day  8
5 15 25
Value
0
1
2
3
4
Co
un
t
Control
GFP< GFP
 GFP< GFP

Day  6 Day  8
E
P
rdm
1
X
bp1
P
ou2af1
Irf4
M
yc
sgRNA-­1
sgRNA-­2
sgNRA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
sgRNA-­1
sgRNA-­2
sgRNA-­3
P
rdm
1
X
bp1
P
ou2af1
Irf4
M
yc
R26-­Cas9iGFP/+
C57BL/6
0.0 0.5 1.0 1.5 2.0
0.
5
1.
0
1.
5
2.
0
Fold  change  of  GFP+  plasmablasts  (Exp.1)  
  F
ol
d  
ch
an
ge
  o
f  G
FP
+  
pl
as
m
ab
la
st
s  
(E
xp
.2
)
Klf6
Brd4 Calm1
Ost4
Pim2
Irf1
Irf4
Junb
Myc Pou2af1
Prkd2
Hsp90b1
Xbp1
Creld2
Zfp36
Arf4
Edem1
Prdm1
0.5 1.0 1.5
0.
0
0.
5
1.
0
1.
5
2.
0
Fold  change  of  GFP+    cells  (Exp.1)
Fo
ld 
ch
an
ge
 o
f G
FP
+  c
ell
s (
Ex
p.
2)
Klf2
Klf6
Ccnd2 Ost4
Cdkn2c
Pik3r1
Egr2
FosbIrf4
Junb
Myc
Pou2af1
Preb
Prkd2
Stat3
Hsp90b1
Xbp1Pomp
Edem1
Dis3
F
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
40LB  feeder  cells
G
H
sg
Ro
sa
26
sg
Pr
dm
1
sg
Os
t4
sg
Ar
f4
sg
Cr
eld
2
sg
Zfp
36
sg
Ed
em
1
0
10
20
30
40
C
D
13
8+
   P
B
s  
(%
)
GFP-  cells
GFP+  cells
Supporting information 
Chu et al.  
 
 
 
Antibodies 
The following anti-mouse antibodies were purchased from Biolegend: anti-B220 (RA3-6B2), 
anti-CD19 (6D5), anti-CD138 (281-2), anti-CD22 (OX-97), anti-CD24 (M1/69), anti-CD44 
(IM7), anti-CD80 (16-10A1), anti-CD81 (Eat-2), anti-CD83 (Michel-19), anti-CD86 (GL-1), anti-
CD45 (30-F11), anti-CD11b (M1/70), anti-Gr-1 (RB6-8C5), anti-CD3ε (145-2C11), anti-Ter-119 
(Ter-119), anti-Ckit (2B8), anti-Sca1 (D7), and anti-CD64 (clone X54-5/7.1). Anti-CD95 (15A7), 
anti-CD14 (clone Sa2-8) and anti-Tnfrsf13b (ebio8F10-3) antibodies were ordered from 
eBioscience. Anti-Cas9 (7A9-3A3) antibody was purchased from Cell Signaling Technology, 
anti-Flag (M2) antibody and anti- β-actin from Sigma. HRP-conjugated secondary anti-mouse 
Ig antibody was ordered from Rockland Immunochemicals. 
  
 
Fig. S1. Characterization of heterozygous R26-Cas9iGFP transgenic mice. (A) FACS plots of 
T cells (CD3+), myeloid cells (CD11b+) and B cells (CD19+) isolated from the mesenteric lymph 
nodes (mLN) of Cas9 transgenic or wildtype animals. (B) FACS plots of B cells (CD19+) 
isolated from the peritoneal cavity and spleen of Cas9 transgenic or wildtype animals. Gates 
were set on B1 and B2 cells in the spleen and B2, B1a and B1b in the peritoneal cavity based 
on CD19, B220, CD43, CD5 and IgM markers as indicated. (C) FACS plots of 
B220+CD19+FashiCD38low germinal center (GC) B cells isolated from the spleen and mLN. 
Data are representative for four independent experiments. Cells from wildtype C57BL/6 
animals (red) and R26-Cas9iGFP/+ animals (blue) are shown in the same FACS plots. 
 
 
	  
  
Fig. S2. Comparison of GFP expression levels in hematopoietic cells of R26-Cas9iGFP and 
R26-Cas9p2aGFP mice. (A) FACS plots of hematopoietic stem cells (defined as Lin-Sca1+c-
Kit+ or LSK), isolated from the bone marrow (BM) of R26-Cas9iGFP/+ (blue), R26-
Cas9p2aGFP/+ (red) and C57BL/6 (black) mice. (B) FACS plots of B cells (CD19+), T cells 
(CD3+), granulocytes (Gr1+CD11b+) and monocytes/dendritic cells (CD11b+Gr1-) isolated from 
the BM and spleen of R26-Cas9iGFP (blue), R26-Cas9p2aGFP (red) and wild-type (black) 
mice. The data are representative for 2 independent experiments. 
 
  
	  
 
Fig. S3. Cas9 levels and localization in primary cells of R26-Cas9iGFP/+ mice and Cas9-dose-
dependent knockout efficiency. (A) Western blots of Cas9 proteins (detected by anti-Cas9 and 
anti-Flag antibodies) in anti-CD40/IL-4-activated B cells and BM-derived macrophages 
(BMDMs) isolated from R26-Cas9iGFP/+ and wildtype animals. Beta-Actin was used as a 
loading control. (B) Immunostaining of Cas9 in BMDMs derived from R26-Cas9iGFP/+ and 
wildtype animals. Cas9 was stained using anti-Flag (M2) antibodies (red). DAPI was used for 
counterstaining of nuclei (green). (C) Knockout efficiencies in B cells from R26-Cas9iGFP/+ 
(top) and R26-Cas9p2aGFP/+ (bottom) mice that were activated and transduced with 
retroviruses expressing sgCD38-1, sgCD38-2, sgFas-1 and sgFas-2 side by side. The gates in 
the FACS plots show the percentage of cells that lost the surface marker 4 days after 
transduction. (D) Western blots of Cas9 proteins in anti-CD40/IL-4-activated B cells isolated 
from R26-Cas9iGFP/+, R26-Cas9p2aGFP/+ and wildtype animals. The data are 
representative for 2 independent experiments. 
 
	  
 
 
 
Fig. S4. Knockout efficiencies in Cas9-expressing B cells. (A) Selection of sgRNAs designed 
with CrispRGold targeting 12 B cell surface makers. Targeting sequences are shown 5’-3’. (B) 
FACS plots showing the knockout efficiencies in Cas9-expressing B cells 4 days after 
transduction with sgRNAs against the indicated surface markers. Note that some surface 
markers are only induced upon activation (CD83 and Tnfrsf13b). The sgRNAs used are 
indicated in the title of each FACS plot. The data are representative for 3 independent 
experiments. 
 
 
  
	  
Fig. S5. CRISPR-mediated gene knockout in primary T cells and BMDMs. (A) Cas9-
expressing T cells were mixed with wild-type T cells. The cells were activated with anti-CD3 
and anti-CD28 antibodies for 2 days. The activated T cells were transduced with retroviral 
particles expressing sgRNAs. The transduced T cells were selected with Puromycin for 4 days 
before assessment of knockout efficiencies. (B) Scheme of CRISPR-mediated gene knockout 
in primary BMDMs. BM cells from R26-Cas9iGFP/+ mice and wild-type mice were 
differentiated for 2 weeks in the presence of M-CSF. BMDMs were transduced with 
lentiviruses expressing sgRNAs targeting mouse CD64 and CD14 genes. The transduced cells 
were selected with Puromycin for 4 days and the gene knockout efficiency was analysed by 
flow cytometry. (C) FACS plots of the transduced BMDMs derived from control animals (top) 
and R26-Cas9iGFP/+ animals (bottom) stained with antibodies against the targeted surface 
markers. The summary of the experiments is shown on the right side. The data are 
representative for 3 individual Cas9 transgenic mice (each representing a data point in the 
summary). 
 
	  
 Fig. S6. Robust detection of transcription factors important for B cell activation and 
differentiation. (A) Scheme of B cell activation and differentiation. Splenic B cells were 
activated with anti-CD40+IL4 and subsequently differentiated into plasmablasts using IL21 and 
CD40-ligand expressing feeder cells. (B) sgRNAs used to target Prdm1, Xbp1, Pou2af1, Irf4 
and Myc. (C) Analysis of the percentage of GFP+ Cas9-expressing B cells and GFP- wild-type 
B cells. These cells were mixed, activated and transduced (individually) with 3 sgRNAs per 
gene targeting Prdm1, Xbp1, Pou2af1, Irf4 and Myc. The FACS plots show the GFP+ Cas9-
expressing B cells 4 and 8 days after transduction. (D) Analysis of the induction of CD138 in 
GFP+ Cas9-expressing and GFP- wildtype B cells 6 days after transduction. The data are 
representative for 3 independent experiments. 
 
 
  
	  
 Fig. S7. Gene set used for the small-scale screen. Total RNA was isolated from follicular B, 
GC and plasma cells that were isolated from the spleen and BM of immunized animals. 
Microarrays were performed and data were normalized prior to analysis. The heat-map shows 
the expression levels of the selected genes with differential expression in the plasma cell 
populations.  
 
  
	  
 
Fig. S8. Small scale-CRISPR-mediated screening to detect novel genes important for B cell 
activation and plasma cell differentiation. (A) Scheme of the high-throughput 96 well-based 
screening approach. One sgRNA was designed for each gene of interest. Each sgRNA was 
separately cloned into a retroviral vector. The cloning, retrovirus production and transduction of 
B cells was performed in 96 well plates. The transduced cells were selected with Puromycin. 
Survival/proliferation was analyzed based on monitoring the percentage of GFP+ Cas9-
expressing B cells at different time points. The fold changes were calculated by comparing to 
the percentage of GFP+ cells at day 2, allowing for the identification of repressor or enhancer 
genes. The plasmablast assay was based on the normalization of GFP+-derived CD138+ 
plasmablasts to GFP--derived CD138+ plasmablasts. (B) Diagram showing the screen set and 
identification of important genes for survival and proliferation (middle, top) and plasma cell 
differentiation (middle, bottom). 22 genes were crucial for activated B cell survival and 
proliferation, and 8 genes were essential for plasma cell generation.10 genes were essential 
for both survival/proliferation and differentiation. 
 
	  
 Fig. S9. Validation of novel candidates important for B cell survival/proliferation and plasma 
cell differentiation. (A) FACS data showing the percentage of GFP+ Cas9 expressing and GFP- 
wildtype B cells 2, 4, 6 and 8 days after transduction with the indicated sgRNAs. As before, 
Cas9-expressing B cells were mixed with wild-type B cells, activated and transduced with 
retroviral particles expressing sgRNA targeting Rosa26 (as control), Myc, Egr2, Dis3, Ost4, 
Preb, and Pomp. (B) Analysis of the induction of CD138 in GFP+ Cas9-expressing and GFP- 
wildtype B cells. Cas9-expressing B cells were mixed with wild-type B cells, activated and 
transduced with retroviral particles expressing sgRNAs targeting Rosa26 (as control), Prdm1, 
Ost4, Arf4, Creld2, Zfp36, and Edem1.  
 
 
 
 
 
	  
